ICOSLG-associated immunological landscape and diagnostic value in oral squamous cell carcinoma: a prospective cohort study

Yuexin Dong, Xinyang Hu, Shixin Xie, Yuxian Song, Yijia He, Wanyong Jin, Yanhong Ni, Zhiyong Wang, Liang DingFrontiers in Cell and Developmental Biology 2023 · DOI

Abstract

Background: We previously reported that stroma cells regulate constitutive and inductive PD-L1 (B7-H1) expression and immune escape of oral squamous cell carcinoma. ICOSLG (B7-H2), belongs to the B7 protein family, also participates in regulating T cells activation for tissue homeostasis via binding to ICOS and inducing ICOS<sup>+</sup> T cell differentiation as well as stimulate B-cell activation, while it appears to be abnormally expressed during carcinogenesis. Clarifying its heterogeneous clinical expression pattern and its immune landscape is a prerequisite for the maximum response rate of ICOSLG-based immunotherapy in a specific population. Methods: This retrospective study included OSCC tissue samples (n = 105) to analyze the spatial distribution of ICOSLG. Preoperative peripheral blood samples (n = 104) and independent tissue samples (n = 10) of OSCC were collected to analyze the changes of immunocytes (T cells, B cells, NK cells and macrophages) according to ICOSLG level in different cellular contents. Results: ICOSLG is ubiquitous in tumor cells (TCs), cancer-associated fibroblasts (CAFs) and tumor infiltrating lymphocytes (TILs). Patients with high ICOSLGTCs or TILs showed high TNM stage and lymph node metastasis, which predicted a decreased overall or metastasis-free survival. This sub-cohort was featured with diminished CD4<sup>+</sup> T cells and increased Foxp3+ cells in invasive Frontier in situ, and increased absolute numbers of CD3<sup>+</sup>CD4<sup>+</sup> and CD8<sup>+</sup> T cells in peripheral blood. ICOSLG also positively correlated with other immune checkpoint molecules (PD-L1, CSF1R, CTLA4, IDO1, IL10, PD1). Conclusion: Tumor cell-derived ICOSLG could be an efficient marker of OSCC patient stratification for precision immunotherapy.

Introduction

Oral squamous cell carcinoma (OSCC) remains a significant clinical challenge due to its high rates of metastasis and recurrence. While immunotherapy has revolutionized cancer treatment, its success in OSCC is currently limited by a lack of precise biomarkers to identify which patients will respond.

Researchers have focused on ICOSLG (Inducible T-cell Costimulator Ligand, also known as B7-H2), a member of the B7 family of costimulatory molecules. While its relative PD-L1 is a well-known target, the role of ICOSLG in the OSCC "immunological landscape"—the complex interaction between tumor cells, structural cells, and immune cells—was previously unclear. Understanding how ICOSLG expression relates to patient outcomes and immune cell behavior is a prerequisite for developing effective ICOSLG-based precision medicine.

Methods

The study employed a multi-pronged approach to map the role of ICOSLG in OSCC, integrating clinical tissue analysis, systemic blood monitoring, and bioinformatic validation.

Experimental process design diagram.
  • Tissue Analysis: 105 OSCC tissue samples were analyzed using immunohistochemistry (IHC) to determine the spatial distribution of ICOSLG across tumor cells (TCs), cancer-associated fibroblasts (CAFs), and tumor-infiltrating lymphocytes (TILs).
  • Peripheral Blood Monitoring: Preoperative blood samples from 104 patients were analyzed via flow cytometry to determine if local tumor markers reflected systemic changes in immune cell populations (T cells, B cells, NK cells).
  • Bioinformatics: To validate findings, the team utilized single-cell RNA sequencing (scRNA-seq) data from the TISCH2 database (including HNSC and LIHC datasets) and genomic data from cBioPortal.

Results and Discussion

Ubiquitous Expression and Prognostic Value

ICOSLG expression was found to be ubiquitous across tumor cells, the surrounding stroma (CAFs), and immune cells. However, its prognostic value is highly specific: only high expression in tumor cells (TCs) and lymphocytes (TILs) significantly predicted poor outcomes. Patients with high ICOSLG in these compartments showed advanced TNM stages and a higher likelihood of lymph node metastasis.

ICOSLG expression across immune, malignant, and stromal cells in HNSC and LIHC datasets.

An Immunosuppressive Signature

High ICOSLG levels were associated with an "exhausted" immune environment. Specifically, these tumors showed a decrease in helper T cells (CD4+) and an increase in regulatory T cells (Foxp3+), which typically act to dampen the anti-tumor immune response. Furthermore, ICOSLG expression positively correlates with other major immune checkpoints, including PD-L1, CTLA4, and IDO1, suggesting it is part of a coordinated "defense shield" used by the tumor to evade the immune system.

Systemic Impact and Survival

Patients with high local ICOSLG expression also showed diminished absolute numbers of CD3+CD4+ and CD8+ T cells in their peripheral blood, suggesting the tumor's influence extends beyond the local site. Consequently, these patients had significantly shorter overall survival (OS) and metastasis-free survival (MFS).

Conclusion

Tumor-derived ICOSLG serves as an efficient marker for stratifying OSCC patients. While further research is needed to clarify the exact molecular signaling pathways and test therapeutic combinations (such as blocking the ICOS-ICOSLG pathway alongside PD-1 inhibitors), these findings pave the way for more personalized and effective immunotherapy strategies in oral cancer.

Summary updated

Abstract

<b>Background:</b> We previously reported that stroma cells regulate constitutive and inductive PD-L1 (B7-H1) expression and immune escape of oral squamous cell carcinoma. ICOSLG (B7-H2), belongs to the B7 protein family, also participates in regulating T cells activation for tissue homeostasis via binding to ICOS and inducing ICOS<sup>+</sup> T cell differentiation as well as stimulate B-cell activation, while it appears to be abnormally expressed during carcinogenesis. Clarifying its heterogeneous clinical expression pattern and its immune landscape is a prerequisite for the maximum response rate of ICOSLG-based immunotherapy in a specific population. <b>Methods:</b> This retrospective study included OSCC tissue samples (n = 105) to analyze the spatial distribution of ICOSLG. Preoperative peripheral blood samples (n = 104) and independent tissue samples (n = 10) of OSCC were collected to analyze the changes of immunocytes (T cells, B cells, NK cells and macrophages) according to ICOSLG level in different cellular contents. <b>Results:</b> ICOSLG is ubiquitous in tumor cells (TCs), cancer-associated fibroblasts (CAFs) and tumor infiltrating lymphocytes (TILs). Patients with high ICOSLGTCs or TILs showed high TNM stage and lymph node metastasis, which predicted a decreased overall or metastasis-free survival. This sub-cohort was featured with diminished CD4<sup>+</sup> T cells and increased Foxp3+ cells in invasive Frontier <i>in situ</i>, and increased absolute numbers of CD3<sup>+</sup>CD4<sup>+</sup> and CD8<sup>+</sup> T cells in peripheral blood. ICOSLG also positively correlated with other immune checkpoint molecules (PD-L1, CSF1R, CTLA4, IDO1, IL10, PD1). <b>Conclusion:</b> Tumor cell-derived ICOSLG could be an efficient marker of OSCC patient stratification for precision immunotherapy.
BibTeX
@inproceedings{dong2023icoslg,
  author = {Yuexin Dong and Xinyang Hu and Shixin Xie and Yuxian Song and Yijia He and Wanyong Jin and Yanhong Ni and Zhiyong Wang and Liang Ding},
  title = {{ICOSLG-associated immunological landscape and diagnostic value in oral squamous cell carcinoma: a prospective cohort study}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  doi = {10.3389/fcell.2023.1257314},
}
Figure